Sandoz signs agreement to acquire antifungal agent Mycamine from Astellas
Advertisement
Basel: Sandoz has signed an agreement to acquire worldwide product rights for systemic antifungal agent Mycamine (micafungin sodium, Funguard in Japan) from Astellas.
Closing is anticipated in the course of H1, 2023, subject to standard conditions and regulatory approvals.
Astellas reported Mycamine sales of JPY 18.9 billion (USD 135 million) for the year ending March 31, 2022. The announcement comes after Sandoz successfully completed the acquisition of GSK’s global cephalosporins portfolio in October 2021.
Read also: CDSCO tells Sandoz to review and report PSUR data of Brolucizumab injection
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.